TP53 and cancer: Given that TP53 deficiencies have myriad downstream consequences on the cell, including e.g. suppression of cell cycle checkpoints, or inactivation of various DNA repair pathways [4] it is conceivable that the TP53 background may affect the activity of various drugs to kill cancer cells, including drugs targeted towards a particular driver mutation outside of TP53 itself.